Controlled Substances Act & Federal Drug Policy

The Controlled Substances Act (CSA, 1970) — codified at 21 U.S.C. Chapter 13 — is the federal law that classifies drugs into five schedules based on abuse potential and accepted medical use, and authorizes the DEA and DOJ to regulate their manufacture, distribution, and possession. Schedule I (heroin, LSD, MDMA, psilocybin, and — critically — marijuana) means the federal government classifies these as having high abuse potential and no currently accepted medical use, making them illegal under federal law regardless of state law. Schedule II covers high-risk drugs with accepted medical use (fentanyl, oxycodone, methamphetamine, cocaine), requiring prescriptions and strict DEA tracking. The most significant current tension: 38+ states have legalized marijuana for medical or recreational use, but marijuana remains Schedule I federally — creating a federal-state legal conflict that affects banking access, federal employment, and criminal penalties for conduct that is legal in the state where it occurs. The DEA, following an HHS recommendation (2023) and Biden administration proposal (2024), is in the process of rescheduling marijuana to Schedule III — a move that would not legalize it federally but would reduce penalties and make federal research easier. The opioid epidemic has led the DEA to impose prescribing quotas on Schedule II opioids and require distributors to flag suspicious orders — a system whose adequacy was questioned in major litigation resulting in $26 billion+ in state settlements with distributors and manufacturers.

Current Law (2026)

Legal Authority

• 21 U.S.C. § 801 — Congressional findings (many drugs have useful medical purposes but also potential for abuse; illegal trafficking constitutes a threat to public health; federal control necessary because drug traffic is interstate and international)
• 21 U.S.C. § 802 — Definitions (controlled substance, schedule, narcotic drug, drug, manufacture, distribute, dispense, administer, practitioner, registration)
• 21 U.S.C. § 811 — Scheduling authority (Attorney General may add/remove/reschedule substances considering: actual/relative abuse potential, scientific evidence, pharmacological effect, history of abuse, risk to public health, psychic/physiological dependence liability, whether the substance is an immediate precursor; AG must request scientific evaluation from HHS; HHS medical/scientific findings are binding)
• 21 U.S.C. § 812 — Schedules of controlled substances (five schedules: I — high abuse potential, no accepted medical use, no accepted safety for use under medical supervision; II — high abuse potential but has accepted medical use; III-V — progressively lower abuse potential; initial placement of substances; examples)
• 21 U.S.C. § 821-829 — Registration and record-keeping (every person who manufactures, distributes, or dispenses controlled substances must register with DEA; quotas for Schedule I and II manufacturing; records and reports required; prescriptions: Schedule II requires written prescription, no refills; III-V allow phone prescriptions and refills)
• 21 U.S.C. § 841 — Prohibited acts (unlawful to manufacture, distribute, or dispense controlled substances except as authorized; unlawful to create, distribute, or possess with intent to manufacture; penalty structure tied to substance type and quantity)
• 21 U.S.C. § 844 — Simple possession (any person who knowingly possesses a controlled substance without a valid prescription is subject to imprisonment up to 1 year; repeat offenders face enhanced penalties)
• 21 U.S.C. § 846 — Attempt and conspiracy (any person who attempts or conspires to commit a drug trafficking offense is subject to the same penalties as the completed offense)
• 21 U.S.C. § 848 — Continuing Criminal Enterprise (CCE — the "drug kingpin" statute; mandatory 20-year minimum for organizing a continuing drug enterprise with 5+ people; life imprisonment for a principal leader)
• 21 U.S.C. § 860 — Enhanced penalties near schools (distribution within 1,000 feet of a school doubles the maximum punishment; mandatory 1-year minimum additional)

Implementing Regulations (21 CFR Parts 1300-1321)

• 21 CFR Part 1301 — Registration of manufacturers, distributors, and dispensers: DEA registration requirements for all handlers of controlled substances; separate registrations for each activity and location; renewal, modification, and revocation procedures
• 21 CFR Part 1304 — Records and reports: every registrant must maintain complete records of controlled substance transactions — receipts, disposals, inventories (biennial); DEA Form 222 for Schedule I-II transfers; electronic prescribing standards
• 21 CFR Part 1306 — Prescriptions: Schedule II prescriptions must be written (no phone-in except emergency with 7-day follow-up); Schedule III-V may be oral or written; refill limits (no refills for Schedule II; up to 5 refills in 6 months for III-V); electronic prescribing for controlled substances (EPCS)
• 21 CFR Part 1308 — Schedules of controlled substances: lists all substances by schedule (I-V); procedures for adding, removing, or rescheduling; temporary scheduling authority for imminent hazards (up to 2 years)
• 21 CFR Part 1311 — Electronic prescribing of controlled substances (EPCS): requirements for electronic prescription applications, identity proofing, two-factor authentication, audit trails
• 21 CFR Part 1314 — Retail sale of scheduled listed chemical products: Combat Methamphetamine Epidemic Act requirements — behind-the-counter placement of pseudoephedrine, logbook, daily/monthly purchase limits, ID verification
• 21 CFR Part 1315 — Importation and production quotas for ephedrine, pseudoephedrine, and phenylpropanolamine: the annual quota system that caps total U.S. production and importation of meth precursor chemicals. Key provisions:
  • § 1315.06 — Four types of quotas: (1) Assessment of Annual Needs — the DEA-fixed aggregate cap on total U.S. production/importation; (2) Individual Manufacturing Quota — each registrant's allocation from the aggregate cap; (3) Procurement Quota — amount a registrant may purchase for further processing; (4) Import Quota — capped authorization for importation of bulk active pharmaceutical ingredients
  • § 1315.11 — Assessment of Annual Needs: the Administrator determines total national need based on legitimate medical, scientific, research, and industrial uses, adjusted for diversion into illicit manufacture. DEA publishes the aggregate assessment each year, and no manufacturer may produce more than its allocated share of the aggregate.
  • § 1315.21–1315.23 — Individual manufacturing quotas: each manufacturer registered to produce bulk ephedrine, pseudoephedrine, or phenylpropanolamine must apply annually by July 1 on DEA Form 189. The DEA allocates based on each applicant's prior year net disposal, estimated needs, and stock in hand — manufacturers who did not need their full prior quota receive reduced future allocations. An inventory allowance of up to 60 days' supply is built into each quota.
  • § 1315.25 — Mid-year increases: a registrant who needs more than its quota (due to increased legitimate demand) may apply for an increase; DEA may approve if the aggregate has not been reached and the additional quota would not contribute to diversion.
  • §§ 1315.31–1315.36 — Procurement quotas: manufacturers of finished dosage forms who buy bulk pseudoephedrine for pressing into tablets must hold a procurement quota — a separate authorization from the manufacturing quota that covers the purchase, not the production. This dual-quota structure means diverters cannot simply acquire chemical by buying from multiple registered manufacturers; each purchase requires its own quota authorization.

The pseudoephedrine quota system is one of the few U.S. examples of a production cap on a legal pharmaceutical ingredient — more typical of Schedule I and II controlled substances. The system was tightened by the Combat Methamphetamine Epidemic Act of 2005 (which added retail purchase limits and logbook requirements at pharmacies under Part 1314) and by ongoing DEA adjustments that reduced aggregate production quotas as illicit methamphetamine switched from pseudoephedrine-based production to precursor chemicals imported from Mexico. The domestic quota cap effectively ended large-scale domestic pseudoephedrine-to-meth "super labs" — the remaining meth supply is now predominantly produced from phenylacetone (P2P) and other non-quota chemicals.

How It Works

The Controlled Substances Act is the foundation of federal drug policy — creating a comprehensive regulatory system that controls the manufacture, distribution, and possession of psychoactive substances through a scheduling framework, registration system, and criminal penalties.

The CSA classifies every controlled substance into one of five schedules based on medical utility, abuse potential, and safety. Schedule I (highest restriction) covers substances with high abuse potential and no currently accepted medical use — heroin, LSD, marijuana (at the federal level), MDMA, psilocybin — which can only be used in DEA-authorized research and cannot be prescribed. Schedule II covers high abuse potential but accepted medical use — fentanyl, oxycodone, hydrocodone, cocaine, methamphetamine, Adderall — requiring written prescriptions, no refills, and strict quantity limits. Schedules III-V cover progressively lower abuse potential, including testosterone (III), benzodiazepines (IV), and codeine-containing cough preparations (V). Scheduling determines everything: prescribing rules, manufacturing quotas, record-keeping, trafficking penalties, and the legal status of possession. The CSA also requires everyone who handles controlled substances to register with the DEA — approximately 1.8 million registrants including physicians, pharmacists, hospitals, manufacturers, distributors, and researchers — with obligations for transaction records, theft reporting, security compliance, and prescribing rules. DEA can revoke registration for violations, effectively ending a practitioner's ability to prescribe.

Criminal penalties under the CSA are tied to substance type and quantity, with mandatory minimums governing trafficking (manufacture and distribution). Key thresholds under 21 U.S.C. § 841: 5 kg+ cocaine, 1 kg+ heroin, or 100 grams+ of fentanyl trigger a 10-year mandatory minimum to life imprisonment; 500 grams+ cocaine, 100 grams+ heroin, or 40 grams+ fentanyl trigger a 5-year minimum to 40 years. Prior felony drug convictions double the mandatory minimums. The Fair Sentencing Act (2010) reduced the crack/powder cocaine sentencing disparity from 100:1 to 18:1, and the First Step Act (2018) made this retroactive while expanding the "safety valve" — allowing judges to sentence below mandatory minimums for qualifying non-violent, non-leadership offenders.

Marijuana remains a Schedule I substance under federal law — the same category as heroin — despite 24 states plus D.C. having legalized recreational use and 38+ states permitting medical marijuana as of 2026. This federal-state conflict means conduct legal under state law remains a federal crime; the DOJ has generally followed a non-enforcement approach for state-licensed operations while Congress has annually prohibited DOJ from spending funds to interfere with state medical marijuana programs (Rohrabacher-Blumenauer amendment). DEA initiated a rescheduling process in 2024 to move marijuana to Schedule III — which would recognize medical use, reduce federal research barriers, and lift the Section 280E tax burden blocking cannabis businesses from deducting ordinary business expenses. The opioid crisis runs parallel: fentanyl — a synthetic opioid 50-100x more potent than morphine, primarily manufactured by Mexican cartels using Chinese precursors — drives approximately 75,000 overdose deaths per year, the deadliest drug crisis in American history. Federal enforcement has focused on border interdiction, international cooperation, and targeting distribution networks, while Congress has debated permanent class-wide scheduling of fentanyl analogs.

How It Affects You

State Variations

Pending Legislation

• S 3618 / HR 6259 — No Fentanyl on Social Media Act. Requires social media platforms to remove content advertising or facilitating the sale of fentanyl and other controlled substances. Status: Introduced.
• S 3330 — Strengthening Sanctions on Fentanyl Traffickers Act. Expands sanctions authority targeting international fentanyl trafficking networks and precursor chemical suppliers. Status: Introduced.
• HR 7552 — CBW Fentanyl Act. Imposes sanctions on foreign persons and entities involved in chemical and biological weapons programs linked to fentanyl production. Status: Introduced.
• S 4209 — Extends the statute of limitations for controlled substance offenses that cause death. Status: Introduced.
• S 3334 — Prohibits reductions in the DEA workforce during the fentanyl crisis. Status: Introduced.
• HR 5744 — Targeting Online Sales of Fentanyl Act. Strengthens enforcement tools against online marketplaces used to traffic fentanyl and precursor chemicals. Status: Introduced.

Recent Developments

• DEA initiated marijuana rescheduling to Schedule III (2024) — the most significant potential change in federal marijuana policy since 1970; administrative proceedings ongoing
• The fentanyl crisis continues to drive enforcement and legislative action, with debate over class-wide scheduling of fentanyl analogs
• The elimination of the X-waiver (2023) removed barriers to buprenorphine prescribing, potentially expanding access to opioid addiction treatment
• Oregon's drug decriminalization experiment (Measure 110, 2020) has been partially rolled back after concerns about implementation and public drug use
• In March 2026, the DEA designated propionyl chloride as a List I chemical under the Controlled Substances Act, reflecting its use in the illicit manufacture of fentanyl and fentanyl analogs — part of the ongoing federal effort to disrupt precursor chemical supply chains fueling the fentanyl crisis.
• In March 2026, the DEA finalized placement of five designer benzodiazepines — clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam — in Schedule I of the Controlled Substances Act, finding these substances have high potential for abuse and no currently accepted medical use.
• MDMA-assisted psychotherapy was under FDA review (2024) for PTSD treatment — if approved, would be the first therapeutic use of a Schedule I psychedelic